Novartis' Cosentyx Wins FDA Approval As First Anti-IL-17 Biologic For Polymyalgia Rheumatica
Novartis AG (NVS) announced FDA approval for Cosentyx 150 mg to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The approval, based on the REPLENISH trial, makes Cosentyx the first anti-IL-17 biologic for this condition. NVS shares closed at $160.20, down 0.19%.
How this was made

The 30-second read
Why it matters
A new FDA-labeled indication can change the addressable market and reimbursement pathway for Cosentyx, while safety signals may affect prescribing behavior and post-marketing surveillance expectations.
Market read
Traders may reassess Cosentyx’s growth trajectory and near-term sentiment for Novartis following a first-in-class anti-IL-17 biologic approval for PMR.
What to watch
The article notes a fatal cryptococcal meningitis case and higher hypersensitivity/UTI rates, which could influence clinician comfort, risk management, and formulary decisions.
Background
Cosentyx (secukinumab) is already approved for multiple inflammatory conditions; this FDA action adds polymyalgia rheumatica as an 11th US indication.
Ticker impact
Novartis said the FDA approved Cosentyx 150 mg for polymyalgia rheumatica, making it the first anti-IL-17 biologic for the indication.
Likely positive bias as the market prices in new indication-driven sales growth, tempered by attention to reported serious adverse events.
The article is a direct, primary FDA approval for a new indication with trial efficacy numbers and safety notes, which typically drives near-term sentiment for the issuer’s commercial outlook.
Market effects
Reinforces IL-17 pathway competitiveness in inflammatory rheumatology and may intensify payer and prescriber evaluation of biologic sequencing versus steroids.
US label expansion can accelerate US prescribing and reimbursement discussions; Japan and other filings are pending.
If Japan and other regulators follow, it could broaden the commercial footprint beyond the US and support longer-dated growth expectations.
Counterpoint
Approval does not guarantee rapid uptake; PMR patients may remain steroid-centric, and real-world adoption could lag trial outcomes and payer restrictions.
Key entities
- companyNovartis AG
Issuer of Cosentyx, which received FDA approval for polymyalgia rheumatica.
- drugCosentyx (secukinumab)
Anti-IL-17A biologic approved for PMR 150 mg in adults with inadequate response to corticosteroids or intolerance to steroid tapering.
- regulatorFDA
Approved the new PMR indication based on the Phase 3 REPLENISH trial.



